This finding suggests that the essence of EC-related neurological changes may be an adaptive compensatory process driven by systemic inflammation (IL-6-mediated microglial activation) and metabolic disorders (albumin deficiency affecting neurotrophic factor transport). This evidence concerns the gene ALB and metabolic disease.